Explore 3 Stock Ideas & Industry Insights Download Free Report

Emmaus Life Sciences Inc

Company price
0.023 USD 0.00(0%)
Last update at 2026-11-17T21:00:00Z
VOLUME
105166
Market Cap
4.32M

Momentum Score

…

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, such as leukemia, lymphoma, and solid tumor cancers. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.02
Low
0.02
High
52 Week Price Range
0.01
Low
0.09
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public disclosures on Emmaus Life Sciences Inc (OTCQB: EMMA) are limited; the company is described in filings as a life sciences firm pursuing therapeutic development. Long-term growth would depend on clinical progress, regulatory approvals, and successful commercialization or licensing, which may support value creation if programs advance.

Key investment risks include early-stage clinical and regulatory execution risk, likely need for additional capital, low trading liquidity typical of an OTCQB listing, and the inherent scientific and market uncertainty of biotech development.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.02
Dividend Yield
-
Revenue TTM
15.53M
Revenue Per Share
0.23
Gross Profit TTM
14.54M
Debt / Equity
-0.74
ROE
-
Net Debt
28.68M
ROCE
-0.48%
Diluted EPS TTM
-0.09

Insight Announcement

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -7.48M -6.42M -3.79M -10.62M -15.92M
Net income -7.49M -6.45M -3.73M -10.69M -15.95M
Selling general administrative 11.05M 16.69M 23.53M 13.17M 13.44M
Selling and marketing expenses - - - 7.49M 5.88M
Gross profit 11.60M 15.45M 28.25M 15.80M 17.30M
Reconciled depreciation 0.04M 0.02M 0.03M 0.05M 0.06M
Ebit - - - -6.64M -6.13M
Ebitda - - - -6.59M -8.04M
Depreciation and amortization - - - 0.05M -1.91M
Operating income 0.23M -1.89M 3.54M -6.59M -6.13M
Other operating expenses - - - 24.98M 26.74M
Interest expense 7.13M 5.49M 7.38M 5.01M 3.10M
Tax provision 0.01M 0.03M -0.06M 0.06M 0.03M
Interest income 0.27M 0.28M 0.68M 0.68M 0.76M
Net interest income -6.86M -5.21M -6.70M -4.33M -2.34M
Income tax expense - - - 0.06M 0.03M
Total revenue 12.45M 16.65M 29.60M 18.39M 20.61M
Total operating expenses 12.22M 18.55M 26.06M 22.39M 23.43M
Cost of revenue 0.86M 1.20M 1.34M 2.59M 3.31M
Total other income expense net -0.85M 0.68M -0.63M -4.04M -9.79M
Net income from continuing ops -7.49M -6.45M -3.73M -10.62M -15.95M
Net income applicable to common shares - - - - -15.95M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 21.44M 23.60M 35.18M 48.23M 56.73M
Other current assets 0.36M 0.23M 0.60M 1.51M 0.39M
Total liab 85.04M 80.08M 82.94M 82.32M 78.18M
Total stockholder equity -63.61M -56.48M -47.76M -34.09M -21.45M
Other current liab 4.58M 6.73M 5.20M 15.82M 5.91M
Common stock - - - 0.05M 0.05M
Capital stock 0.07M 0.06M 0.06M 0.05M 0.05M
Retained earnings -270.07M -262.57M -256.12M -252.34M -241.27M
Other liab - - - - 33.17M
Other assets - - - - 0.29M
Cash 2.13M 1.39M 2.55M 2.02M 2.28M
Total current liabilities 69.07M 63.55M 61.51M 54.32M 37.10M
Current deferred revenue - - - 10.00M 6.61M
Net debt 28.68M 28.34M 27.40M 23.08M 27.64M
Short term debt - - - 24.72M 22.00M
Short long term debt 28.53M 27.48M 27.72M 23.84M 21.26M
Short long term debt total - - - 25.10M 29.91M
Other stockholder equity - - - 220.81M 220.02M
Property plant equipment - - - - 3.63M
Total current assets 7.75M 6.77M 11.51M 6.29M 9.09M
Long term investments - - 0.00M 18.83M 17.62M
Net tangible assets - - - - -21.45M
Short term investments - - - -19.97M -
Net receivables 2.80M 2.62M 5.52M 0.38M 1.04M
Long term debt 2.27M 2.25M 2.23M 3.73M 4.65M
Inventory 1.55M 1.64M 1.71M 2.38M 4.39M
Accounts payable 4.03M 3.31M 3.63M 3.79M 2.58M
Accumulated other comprehensive income - - - -2.62M -0.26M
Non currrent assets other 0.21M 0.22M 0.30M 0.26M 26.39M
Non current assets total 13.69M 16.84M 23.67M 41.94M 47.64M
Capital lease obligations 1.76M 3.24M 3.48M 3.26M 4.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 2.17M 2.51M 2.23M -2.39M -6.38M
Change to liabilities - - - 0.00M 2.06M
Total cashflows from investing activities - - - - -6.38M
Net borrowings -1.43M -1.35M 2.48M - 7.41M
Total cash from financing activities -1.43M -1.35M 2.48M 7.23M 7.41M
Change to operating activities - - - - 0.46M
Net income -7.49M -6.45M -3.73M -10.62M -15.95M
Change in cash 0.74M -1.16M 0.53M -0.26M -0.21M
Begin period cash flow 1.39M 2.55M 2.02M 2.28M 2.49M
End period cash flow 2.13M 1.39M 2.55M 2.02M 2.28M
Total cash from operating activities -0.01M -2.29M -1.50M -5.07M -1.25M
Issuance of capital stock - - - - 0.00M
Depreciation 0.04M 0.02M 0.03M 0.05M 0.06M
Other cashflows from investing activities - - - - -6.30M
Change to inventory -0.02M 0.01M 0.65M 0.43M 0.46M
Change to account receivables -0.18M 2.90M -5.15M 0.61M -0.84M
Other cashflows from financing activities - - - 10.37M 16.19M
Change to netincome - - - 1.48M 10.71M
Capital expenditures 0.00M 0.01M 0.02M 0.03M 0.07M
Change in working capital 5.91M 4.20M -2.62M 2.21M 2.11M
Stock based compensation 0.03M 0.26M 1.26M 0.02M 0.55M
Other non cash items 0.56M -0.32M 2.57M 3.27M 2.31M
Free cash flow -0.01M -2.30M -1.52M -5.10M -1.33M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
EMMA
Emmaus Life Sciences Inc
-
-%
0.02 - 11.90 0.28 35.48 2.09 12.71
NVO
Novo Nordisk A/S
-1.25
3.07%
39.45 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-
-%
536.45 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-9.75
1.02%
948.01 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Emmaus Life Sciences Inc

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, such as leukemia, lymphoma, and solid tumor cancers. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.

21250 Hawthorne Boulevard, Torrance, CA, United States, 90503

310 214 0065

32

Name Title Year Born
Dr. Yutaka Niihara M.D., M.P.H, M.P.H. Chairman & CEO 1960
Mr. Willis C. Lee M.S. Vice Chairman & COO 1960
Mr. Yasushi Nagasaki CPA, CPA Chief Financial Officer 1967
Mr. George Sekulich Sr. VP of Global Commercialization & Chief Information Officer 1966
Mr. Dale E. Short J.D. Gen. Counsel NA
Dr. Charles W. Stark Pharm.D, Pharm.D. Sr. VP of Medical Affairs, Clinical, Regulatory 1955
Mr. Kurt H. Kruger M.B.A., M.S. Consultant 1955
Mr. S. Steven Lee Independent Consultant 1966
Mr. Willis C. Lee M.S. CEO & Chairman of the Board 1960
Ms. Hiroko Huynh CPA Chief Accounting Officer 1980

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…